Acetamide stereoisomer
The compound of formula (I) is a water-stable, long acting β 2 -selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.
1. A compound of formula (I)
or a pharmaceutically acceptable salt thereof.
2. A mixture of isomers of N-[2-hydroxy-5-[1-hydroxy-2-[[(2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-phenyl]acetamide, wherein the mixture comprises at least 90% by weight of the isomer
3. A compound of general formula (IV)
or a salt thereof, in which P 1 and P 2 each represents a hydrogen atom or a hydroxyl protecting group, and P 3 represents a hydrogen atom or a benzylic amine protecting group, provided that at least one of P 2 and P 3 represents a protecting group.
4. A pharmaceutical composition, which comprises a compound as claimed in claim 1 or claim 2 and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition as claimed in claim 4 , which further comprises a steroid.
6. A pharmaceutical composition as claimed in claim 5 , in which the steroid is beclomethasone, triamcinolone, funisolide, mometasone, budesonide or fluticasone.
7. A pharmaceutical composition as claimed in any one of claims 4 to 6 , which further comprises a muscarinic receptor antagonist.
8. A pharmaceutical composition as claimed in claim 7 , in which the muscarinic receptor antagonist is ipratropium or tiatropium.
9. A pharmaceutical composition as claimed in any one of claims 4 to 8 which further comprises an anticholinergic.
10. A pharmaceutical composition as claimed in claim 9 , in which the anticholinergic is glycopyrralate.
11. A pharmaceutical composition as claimed in any one of claims 4 to 10 which further comprises a mucolytic.
12. A pharmaceutical composition as claimed in claim 11 , in which the mucolytic is cromoglycate, acetylcysteine, arginine, or 2-mercaptoethanesulphonate.
13. A pharmaceutical composition as claimed in any one of claims 4 to 12 which further comprises an anti-inflammatory agent.
14. A pharmaceutical composition as claimed in claim 13 , in which the anti-inflammatory agent is an inhibitor of tumor necrosis factor alpha (TNFα) or dipeptidyl peptidase IV, and/or antibodies to pro-inflammatory interleukins such as IL4 and IL13.
15. A method for treating bronchoconstriction associated with a reversible obstructive airways disease, which comprises administering to a patient in need of treatment, an effective amount of a compound as claimed in claim 1 .